Abstract
The clinical characteristics and prognosis of intracranial hemorrhage (ICH) in patients with hematological diseases remain controversial. This study aimed to describe the clinical characteristics and explore the prognostic factors in such patients. A total of 238 ICH patients with a hematological disease were recruited from the Institute of Hematology and Blood Diseases Hospital, China, from January 2015 to April 2020. The Cox proportional hazards model was used to identify the prognostic factors for 30-day mortality in ICH patients with a hematological disease. There were 123 cases of acute leukemia (AL), 20 of myelodysplasia/myeloproliferative neoplasm, 35 of aplastic anemia (AA), 29 of immune thrombocytopenia (ITP), 19 of congenital/acquired coagulation factor deficiency, and 12 of other hematological diseases. Furthermore, 121 patients presented with a multi-site hemorrhage (MSH), 58 with a single-site hemorrhage in the brain parenchyma (PCH), 23 with a subarachnoid hemorrhage, 33 with a subdural hemorrhage (SH), and three with an epidural hemorrhage. The Cox proportional hazards model indicated association of SH (vs PCH, hazard ratio [HR]: 0.230; 95% confidence interval [CI]: 0.053–0.996; P = 0.049), low white blood cells (≤ 100 × 109/L vs > 100 × 109/L, HR: 0.56; 95% CI: 0.348–0.910; P = 0.019), AA (vs AL, HR: 0.408; 95% CI: 0.203–0.821; P = 0.012), and ITP (vs AL, HR: 0.197; 95% CI: 0.061–0.640; P = 0.007) with improved 30-day mortality. However, increased age (HR: 1.012; 95% CI: 1.001–1.022; P = 0.034), MSH (vs PCH, HR: 1.891; 95% CI: 1.147–3.117; P = 0.012), and a disturbance of consciousness (HR: 1.989; 95% CI: 1.269–3.117; P = 0.003) were associated with increased risk of 30-day mortality. In conclusion, in this study, we revealed the clinical characteristics of Chinese ICH patients with a hematological disease. Moreover, we identified risk factors (age, white blood cells, AA, ITP, SH, MSH, and a disturbance of consciousness) that may influence 30-day mortality.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Hematological diseases often present with cerebrovascular complications, including ischemic stroke, intracranial hemorrhage (ICH), microbleeds, posterior reversible encephalopathy syndrome, and dural sinus and cerebral vein thrombosis [1]. A previous study found that the prevalence of stroke in patients with hematological diseases ranged from 0 to 7% [2]. Various hematological disorders may play a direct or indirect role in neurological complications and ICH [3, 4]. Previous studies have already identified hypertension, vessel wall abnormality, invasion or compression of vessels by a tumor in or adjacent to the brain, low platelet count or platelet dysfunction, coagulation factor deficiency, disseminated intravascular coagulation, sepsis, and hyperleukocytosis as independent risk factors for ICH in cancer patients [5,6,7]. However, the clinical characteristics and prognostic factors in ICH patients with a hematological disease remain controversial.
The pathogenesis of ICH differs in the general and hematological disease populations. The pathogenic mechanisms include abnormal platelet counts or function, coagulation disorders, hyperleukemia, sepsis, and abnormal vessel walls [6,7,8]. ICH may occur at various timepoints after the diagnosis of hematological disease, especially for patients who firstly experienced hematological disease [9, 10]. Moreover, most hemorrhages in patients with a hematological disease occur in the brain parenchyma, with variable clinical characteristics [11, 12]. The prognosis of ICH patients with hematological diseases has improved because of the development of modern neuroimaging and advances in hematology and neurology [12, 13].
However, epidemiological data on ICH patients with hematological diseases in China are lacking. Therefore, we performed a retrospective single-center study to describe the clinical characteristics and prognostic factors in ICH patients with a hematological disease in China.
Methods
Patient population
A total of 238 imaging-confirmed ICH patients with hematological disease attending the Institute of Hematology and Blood Diseases Hospital, Tianjin, China, from January 2015 to April 2020, were analyzed retrospectively. The study was approved by the Institutional Review Board of the Institute of Hematology and Blood Diseases Hospital.
The types of hematological diseases included acute lymphoblastic leukemia, acute myeloid leukemia (AML), acute mixed phenotype leukemia, myelodysplastic syndrome (MDS), atypical chronic granulocytic leukemia (aCML), chronic myelocytic leukemia (CML), chronic myelomonocytic leukemia (CMML), aplastic anemia (AA), immune thrombocytopenia (ITP), hemophilia, acquired hemophilia, vitamin-dependent coagulation factor deficiency, hereditary coagulation factor VII deficiency, non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM), pure red blood cell aplastic anemia (PRCA), Evans syndrome, Fanconi anemia, connective tissue disease combined with abnormal blood cell counts, and hypersplenism. These were grouped into three: Firstly, the MDS/MPN group included MDS, aCML, CML, and CMML. Secondly, the congenital/acquired coagulation factor deficiency (CCFD/ACFD) group included hemophilia, acquired hemophilia, vitamin-dependent coagulation factor deficiency, hereditary coagulation factor VII hemophilia, acquired hemophilia, vitamin-dependent coagulation factor deficiency, and hereditary coagulation factor deficiency. Thirdly, the other group included NHL, MM, PRCA, Evans syndrome, Fanconi anemia, connective tissue disease with abnormal blood counts, and hypersplenism.
Cranial computerized tomography was performed in all patients with a hematological disease, and their cranial hemorrhage site; hemorrhage characteristics, signs, and symptoms; and the presence of any co-infections were recorded. However, the extent of hemorrhage was not known, because most of the hemorrhages were diffuse and multifocal.
ICH included parenchymal hemorrhage (PCH), subarachnoid hemorrhage (SCH), subdural hemorrhage (SH), epidural hemorrhage (EH), and multi-site hemorrhage (MSH). PCH was defined as a single-site hemorrhage that occurred in the brain parenchyma, while MSH was defined as hemorrhages in multiple parts of the brain parenchyma combined with hemorrhages in other parts of the brain parenchyma.
The signs and symptoms included headache, disturbance of consciousness, mental disorder, meningeal irritation sign, hemiplegia, epilepsy, aphasia, and dysopia.
Data collection and definition
The baseline characteristics recorded included age, sex, hypertension, diabetes mellitus (DM), intracranial hemangioma, and cranial trauma. Patients with acute promyelocytic leukemia (APL) received plasma or fibrinogen infusions if fibrinogen ≤ 1.5 g/L, while platelets were transfused if platelet ≤ 30 × 109/L in these patients. For non-APL patients, red blood cells were infused when hemoglobin ≤ 70 g/L, plasma or fibrinogen was infused if fibrinogen ≤ 1.0 g/L, and platelets were transfused if platelets ≤ 10 × 109/L. Thrombocytopenia was defined as platelets ≤ 30 × 109/L in patients with APL, platelets ≤ 20 × 109/L in patients with acute leukemia other than APL, and platelets ≤ 10 × 109/L in patients with diseases other than these two categories. Coagulation abnormalities were defined as international normalized ratio (INR) > 1.4, and/or partial thromboplastin time (APTT) > 50 s, and/or fibrinogen concentration ≤ 1.5 g/L. Leukocytosis was defined as leukocytes > 100 × 109/L. Serum urea and creatinine levels were also recorded, and patients were accordingly divided into normal and abnormal groups. All data were collected within 3 days for hematological disease patients diagnosed with ICH.
ICH management and prognosis
Medical management of ICH in patients with a hematological disease included conservative and surgical treatments. Conservative treatment strategies included red blood cell, platelet, plasma, and fibrinogen support therapy; the use of hemostasis and dehydration to reduce cranial pressure; and control of the original disease as well as comorbidities. Surgical treatment was determined by the neurosurgeon after consultation and evaluation of the patient’s condition. Mortality events and the times of mortality were recorded after follow-up to 30 days from the inception of ICH.
Statistical analysis
Continuous variables are presented as means (standard deviations) or medians (quartiles), according to the data distribution, and categorical variables are presented as numbers (percentages). The differences among groups were calculated using analysis of variance and chi-squared tests. The Kaplan–Meier method was used for survival analysis. Univariate analysis was performed using the Log-rank approach. A Cox proportional hazards model was used to identify the prognostic factors for mortality in ICH patients with a hematological disease. All reported P values were two-sided, and statistical significance was set at P < 0.05. All statistical analyses were conducted using SPSS software (Version: 22.0; Chicago, IL, USA).
Results
Patients’ characteristics
Of the 238 included patients, 123 patients had AL, 20 had MDS/MPN, 35 had AA, 29 had ITP, 19 had CCFD/ACFD, and 12 had other types of hematological diseases. ICH occurred during induction therapy in 218 patients, while 20 patients presented ICH during consolidation therapy. With respect to the bleeding sites, 121 patients presented with MSH, 58 with PCH, 23 with SCH, 33 with SH, and three with EH. We noted that the bleeding sites were different in patients with different types of hematological diseases (P < 0.001; Table 1).
Clinical characteristics according to the type of hematological disease
The characteristics of recruited patients according to the types of hematological diseases are presented in Table 2. Age (P = 0.036), sex (P = 0.002), thrombocytopenia (P < 0.001), INR (P = 0.011), APTT (P < 0.001), FIB (P < 0.001), white blood cell count (P < 0.001), intracranial hemangioma (P = 0.006), cranial trauma (P = 0.004), disease status (P < 0.001), coagulation abnormalities (P < 0.001), co-infection (P < 0.001), and serum urea (P = 0.026) differed significantly among the patients with different types of hematological diseases. However, the distribution of hypertension, diabetes, headache, disturbance of consciousness, mental disorder, meningeal irritation sign, hemiplegia, epilepsy, aphasia, dysopia, and serum creatinine levels were not significantly different among patients with the different types of hematological diseases.
Clinical characteristics according to bleeding sites
The characteristics of the recruited patients according to the bleeding sites are presented in Table 3. APTT (P = 0.009), FIB (P = 0.022), white blood cell count (P < 0.001), cranial trauma (P < 0.001), disease status (P = 0.007), headache (P = 0.006), disturbance of consciousness (P = 0.002), meningeal irritation sign (P < 0.001), hemiplegia (P < 0.001), and co-infection (P = 0.002) were significantly associated with bleeding sites. However, the distribution of age, sex, thrombocytopenia, INR, hypertension, diabetes, intracranial hemangioma, mental disorder, epilepsy, aphasia, dysopia, coagulation abnormalities, serum urea, and serum creatinine did not show a significant association with any bleeding site.
Prognostic factors
The prognostic factors for 30-day mortality in ICH patients with a hematological disease are presented in Table 4. Univariate analysis showed that SCH (hazards ratio [HR]: 0.101; 95% confidence interval [CI]: 0.013–0.809; P = 0.031) and SH (HR: 0.187; 95% CI: 0.041–0.858; P = 0.031) were associated with an improvement in the 30-day mortality, as compared with PCH. Moreover, patients with M3 hematological disease had better 30-day mortality than those with non-M3 hematological disease (HR: 0.425; 95% CI: 0.209–0.866; P = 0.018). Furthermore, patients with AA (HR: 0.294; 95% CI: 0.135–0.639; P = 0.002) and ITP (HR: 0.135; 95% CI: 0.038–0.477; P = 0.002) had a better prognosis than those with AL. Finally, disturbance of consciousness (HR: 2.231; 95% CI: 1.294–3.846; P = 0.004) and coagulation abnormalities (HR: 4.823; 95% CI: 1.014–22.935; P = 0.048) were associated with a poor prognosis in terms of 30-day mortality.
Multivariate analysis showed that SH was associated with a better 30-day mortality (HR: 0.230; 95% CI: 0.053–0.996; P = 0.049), while MSH was associated with a poor 30-day mortality, as compared with PCH (HR: 1.891; 95% CI: 1.147–3.117; P = 0.012). Moreover, a low white blood cell count was associated with a lower risk of 30-day mortality (HR: 0.563; 95% CI: 0.348–0.910; P = 0.019). Furthermore, AA (HR: 0.408; 95% CI: 0.203–0.821; P = 0.012) and ITP (HR: 0.197; 95% CI: 0.061–0.640; P = 0.007) were associated with an improved 30-day mortality, as compared with AL. Finally, increased age (HR: 1.012; 95% CI: 1.001–1.022; P = 0.034) and presentation with a disturbance of consciousness (HR: 1.989; 95% CI: 1.269–3.117; P = 0.003) were associated with an increased risk of 30-day mortality.
Discussion
ICH is more common in patients with a hematological disease than in the general population, and is a serious complication and cause of death in these patients [14,15,16,17,18]. In this study, 238 patients with a hematological disease who presented with ICH were retrospectively recruited and their characteristics observed. Most patients with hematological disease who developed ICH had MSH. The type of hematological disease in patients with ICH differed by age, sex, thrombocytopenia, INR, APTT, FIB, white blood cell count, intracranial hemangioma, cranial trauma, disease status, coagulation abnormalities, co-infection, and serum urea. Furthermore, bleeding sites differed by APTT, FIB, white blood cell count, cranial trauma, disease status, headache, disturbance of consciousness, meningeal irritation sign, hemiplegia, and co-infections in patients with a hematological disease. Finally, the 30-day mortality for ICH patients with hematological disease may be influenced by age, white blood cell count, AA, ITP, SH, MSH, and presentation with a disturbance of consciousness.
This study described the clinical characteristics of ICH in Chinese patients with a hematological disease, which have not been reported previously, and identified prognostic factors for the 30-day mortality in these patients. A previous study conducted by Chen et al. recruited 2574 adult patients with hematological malignancies and found that the incidence of ICH was 2.8% and that the risk of ICH in patients with AML was higher than that in patients with other hematological malignancies [19]. They found that patients who presented with central nervous system–involved lymphomas had a higher risk of ICH than patients with central nervous system–involved AL [19]. Furthermore, the type of hematological malignancies was not associated with mortality [19]. However, that study did not focus on ICH patients with a hematological disease, and the prognostic factors for the 30-day mortality in ICH patients with a hematological disease were not identified. Therefore, we performed this retrospective study to describe the clinical characteristics of ICH patients with a hematological disease and to identify the prognostic factors for 30-day mortality in these patients.
In our study, most patients had MSH; this was not consistent with findings from prior studies [20,21,22], which found that the most common site of ICH in hematological disorders was a single cortico-parietal area, with much lower incidences of subcortical and cerebellar hemorrhages. Moreover, the most common site of cerebral hemorrhage in patients with hypertension was a hemorrhage in the basal ganglia region. We noted that the sites of ICH varied among the different hematological diseases: (1) The most common bleeding sites for AL patients were MSH and PSH; (2) MSH and SCH were the most common sites in MDS/MPN and AA patients; (3) the most common bleeding site in ITP patients was SH; and (4) MSH and SH were the most common sites in CCFD/ACFD patients. Finally, the symptoms of headache, nausea, vomiting, lateral motor and sensory disturbances, and disturbance of consciousness were relatively common, while mental disorders, meningeal irritation sign, epilepsy, aphasia, and dysopia were relatively uncommon.
Our study found there were significant differences in the age, sex, thrombocytopenia, INR, APTT, FIB, white blood cell counts, intracranial hemangioma, cranial trauma, disease status, coagulation abnormalities, co-infections, and serum urea levels, among patients with the various types of hematological diseases. However, these results were obtained from univariate analysis, and the patients included had various types of hematological diseases, which could have caused some instability in the results. Furthermore, the bleeding sites in patients with a hematological disease may have been affected by APTT, FIB, white blood cell count, cranial trauma, disease status, headache, disturbance of consciousness, meningeal irritation sign, hemiplegia, and co-infection. However, the vascular risk factors did not affect the bleeding sites. These factors included hypertension, diabetes, intracranial hemangioma, and cranial trauma, which were significantly different from the general population and reflect the unique pathophysiological characteristics of ICH in patients with a hematological disease [23,24,25]. This may have been due to the elevated levels of the white blood cells, resulting from infiltration of the vascular wall, as these patients are prone to vascular endothelial injuries, and release of procoagulant substances and inflammatory markers, which could increase the risk of ICH [26, 27]. Moreover, the APTT and FIB values reflected coagulation abnormalities, which was associated with an increased risk of bleeding [28, 29]. The signs and symptoms of patients may reflect the severity of disease, with the distribution being related significantly to the bleeding sites.
This study found that the 30-day mortality in ICH patients with a hematological disease was 41.2%, which was significantly higher than that in the general population with ICH [15, 30]. The prognostic factors for the 30-day mortality in ICH patients with a hematological disease included age, white blood cell count, AA, ITP, SH, MSH, and a disturbance of consciousness. This may have been because ICH was regarded as secondary to vascular rupturing caused by the leukemia and thrombosis and necrosis of the ischemic tissue [31]. Moreover, AA and ITP are considered to be benign hematological diseases, and prognosis for ICH patients with AA and ITP is relatively better than that of AL patients with ICH, which may be attributed to AL patients being associated with and being more prone to co-infections, coagulation abnormalities, and elevated white blood cell levels. Furthermore, the bleeding sites and the presence of a disturbance of consciousness have been significantly related to the severity of the disease, which may have affected the prognosis of ICH patients with a hematological disease [12]. Finally, infection has been reported to be the main cause of death in patients with hematological malignancies [32]. In our study, most death events (82, 34.5%) occurred within 4 days in patients diagnosed with ICH, while progression of disease or infection contributed less to death events within 4 days.
Certain shortcomings of this study should be acknowledged. First, the current study was a retrospective study, and thus, selective and recall biases were inevitable. Second, the number of patients in the various hematological disease groups was not balanced. Third, the chronic worsening thrombocytopenia and transfusion refractoriness in patients with MDS or CMML resulted in a poor treatment effect and poor prognosis. Fourth, data on the treatment strategies used for hematological diseases, which may have affected the prognosis of ICH patients with a hematological disease, were not available. Finally, stratified analyses were not performed due to the small number of patients with a specific bleeding site.
Conclusions
The findings of this study systematically describe the clinical characteristics of Chinese ICH patients with a hematological disease. Most of our patients had MSH, and age, sex, thrombocytopenia, INR, APTT, FIB, white blood cells, intracranial hemangioma, cranial trauma, disease status, coagulation abnormalities, co-infection, and serum urea differed among patients with various types of hematological diseases. Moreover, APTT, FIB, white blood cell, cranial trauma, disease status, headache, disturbance of consciousness, meningeal irritation sign, hemiplegia, and co-infection were significantly associated with the bleeding sites. Finally, age, white blood cells, AA, ITP, SH, MSH, and disturbance of consciousness were significantly associated with 30-day mortality in ICH patients with a hematological disease. Further prospective studies should be performed to verify the findings of this study and to assess the prognostic factors in patients with a specific hematological disease.
Data availability
All relevant summary data are provided in the manuscript text, and tables. Further inquiries can be directed to the corresponding author.
References
Gonzalez-Duarte A, Garcia-Ramos GS, Valdes-Ferrer SI et al (2008) Clinical description of intracranial hemorrhage associated with bleeding disorders. J Stroke Cerebrovasc Dis 17:204–207
Arboix A, Jiménez C, Massons J, Parra O, Besses C (2016) Hematological disorders: a commonly unrecognized cause of acute stroke. Expert Rev Hematol 9:891–901
Glass J (2006) Neurologic complications of lymphoma and leukemia. Semin Oncol 33:342–347
Grisold W, Oberndorfer S, Struhal W (2009) Stroke and cancer: a review. Acta Neurol Scand 119:1–16
Rogers LR (2010) Cerebrovascular complications in patients with cancer. Semin Neurol 30:311–319
Rogers LR (2008) Management of stroke in cancer. Curr Oncol Rep 10:72–77
Rogers LR (2003) Cerebrovascular complications in cancer patients. Neurol Clin 21:167–192
Rickles FR, Falanga A, Montesinos P et al (2007) Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? Thromb Res 120:S99-106
Kim IY, Jung S, Jung TY et al (2008) Primary central nervous system lymphoma presenting as an acute massive intracerebral hemorrhage: case report with immunohistochemical study. Surg Neurol 70:308–311
Balmages A, Dinglasan J, Osborn MB (2018) Severe intracranial hemorrhage at initial presentation of acute myelogenous leukemia. Clin Pract Cases Emerg Med 2:203–206
Yuguang L, Meng L, Shugan Z et al (2002) Intracranial tumoural haemorrhage: a report of 58 cases. J Clin Neurosci 9:637–639
Owattanapanich W, Auewarakul CU (2016) Intracranial hemorrhage in patients with hematologic disorders: prevalence and predictive factors. J Med Assoc Thai 99:15–24
Kase CS (1986) Intracerebral hemorrhage: non-hypertensive causes. Stroke 17:590–595
Choy DK, Wu PH, Tan D et al (2010) Correlation of the long-term neurological outcomes with completeness of surgical evacuation in spontaneous supratentorial intracerebral haemorrhage: a retrospective study. Singapore Med J 51:320–325
Mendelow AD, Gregson BA, Fernandes HM et al (2005) Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 365:387–397
Proust F, Leveque S, Derrey S et al (2007) Spontaneous supratentorial cerebral hemorrhage: role of surgical treatment. Neurochirurgie 53:58–65
Qureshi AI, Mendelow AD, Hanley DF (2009) Intracerebral haemorrhage. Lancet 373:1632–1644
Sacco S, Marini C, Toni D et al (2009) Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke 40:394–399
Chen CY, Tai CH, Cheng A et al (2012) Intracranial hemorrhage in adult patients with hematological malignancies. BMC Med 10:97
Kim H, Lee JH, Choi SJ et al (2006) Risk score model for fatal intracranial hemorrhage in acute leukemia. Leukemia 20:770–776
Choi YJ, Rha HK, Park HK et al (2004) Intracranial hemorrhage in patients with hematologic disorders. J Korean Neurosurg Soc 36:302–305
Choudhry A, DeLoughery TG (2012) Bleeding and thrombosis in acute promyelocytic leukemia. Am J Hepatol 87:596–603
Yamauchi K, Umeda Y (1997) Symptomatic intracranial haemorrhage in acute nonlymphoblastic leukaemia: analysis of CT and autopsy findings. J Neurol 244:94–100
Kawanami T, Kurita K, Yamakawa M et al (2002) Cerebrovascular disease in acute leukemia: a clinicopathological study of 14 patients. Intern Med 41:1130–1134
Wurthner JU, Kohler G, Behringer D et al (1999) Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis: a clinicopathologic report of four cases. Cancer 85:368–374
Pastore F, Pastore A, Wittmann G et al (2014) The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS ONE 9:e95062
Röllig C, Ehninger G (2015) How I treat hyperleukocytosis in acute myeloid leukemia. Blood 125:3246–3252
Nadir Y, Katz T, Sarig G et al (2005) Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematologica 90:1549–1556
Dubois C, Schlageter MH, de Gentile A et al (1994) Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. Blood 83:3264–3270
Hemphill JC III, Bonovich DC, Besmertis L et al (2001) The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 32:891–897
Ichikawa K, Edahiro Y, Gotoh A et al (2016) Co-occurrence of hyperleukocytosis and elevated fibrin-fibrinogen degradation product levels is a risk factor for early intracranial hemorrhage in patients with de novo acute leukemia. Int J Hematol 104:612–620
Zembower TR (2014) Epidemiology of infections in cancer patients. Cancer Treat Res 161:43–89
Acknowledgements
We thank the editors from Editage for language polishing of the paper.
Author information
Authors and Affiliations
Contributions
LDP and ZJY contributed to the design of the study. ZJY and LY contributed to the acquisition of data. ZJY and MYS performed the analyses. ZJY, SXJ, LYZ, YYK, HB, SMH, LQL, and MYC contributed to the interpretation of data. LDP and ZJY drafted the manuscript. All authors contributed to the critical revision of the manuscript. All authors read and approved the submitted version.
Corresponding author
Ethics declarations
Ethics approval
The study was approved by the Institutional Review Board of the Institute of Hematology and Blood Diseases Hospital.
Consent to participate
Not applicable.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhang, JY., Li, Y., Ma, YS. et al. Clinical characteristics and prognostic factors in intracranial hemorrhage patients with hematological diseases. Ann Hematol 101, 2617–2625 (2022). https://doi.org/10.1007/s00277-022-04982-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-022-04982-w